Our pick for this week is in the speculative arena of stem cell research. With the Obama administration lifting the restrictions on federal funding of this technology, it should cause a temporary run in stocks in this industry. Stemcells Inc. (STEM) a clinical-stage biotechnology company, engages in the discovery,
development, and commercialization of cell-based therapeutics to treat
diseases of the central nervous system and liver. Buy Stock Under $1.50 Stop @ $1.25